SG11201805142RA - Pharmaceutical compositions comprising phenylaminopyrimidine derivative - Google Patents
Pharmaceutical compositions comprising phenylaminopyrimidine derivativeInfo
- Publication number
- SG11201805142RA SG11201805142RA SG11201805142RA SG11201805142RA SG11201805142RA SG 11201805142R A SG11201805142R A SG 11201805142RA SG 11201805142R A SG11201805142R A SG 11201805142RA SG 11201805142R A SG11201805142R A SG 11201805142RA SG 11201805142R A SG11201805142R A SG 11201805142RA
- Authority
- SG
- Singapore
- Prior art keywords
- natco
- hyderabad
- house
- road
- international
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 11M1111101110101011111 HO 11111011101011111 001111011111011111110111011# International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ..... .....!;,' WO 2017/103941 Al 22 June 2017(22.06.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/14 (2006.01) A61K 9/08 (2006.01) kind AO, of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/IN2016/050035 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 30 January 2016 (30.01.2016) KZ, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 6951/CHE/2015 18 December 2015 (18.12.2015) IN (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: NATCO PHARMA LTD [IN/IN]; Natco GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, House, Road No.2, Banjara Hills, Hyderabad 500034 (IN). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors: PARVATANENI, Durga Maheswari; Natco TJ, TM), House, Road No.2, Banjara Hills, Hyderabad 500034 (IN). DK, European (AL, AT, BE, BG, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MOHANTY, Mitrabhanu; Natco House, Road No.2, LV, SM, Banjara Hills, Hyderabad 500034 (IN). APPAD- GW, KM, ML, MR, NE, SN, TD, TG). WEDULA, Venkata Satyanarayana; Natco House, Road MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, — No.2, Banjara Hills, Hyderabad 500034 (IN). AD- Declarations under Rule 4.17: IBHATLA, Kali Satya Bhujanga Rao; Natco House, of inventorship (Rule 4.17(iv)) Road No.2, Banjara Hills, Hyderabad 500034 (IN). NAN- NAPANENI, Venkaiah Chowdary; Natco House, Road Published: No.2, Banjara Hills, Hyderabad 500034 (IN). — with international search report (Art. 21(3)) = = = = = = = = = = = Il Il 7r C:r M © Il IN 1-1 (54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE 0 N (57) : An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically en. ) acceptable salts and polymorphs thereof, by dispersing in a polymer system in a fmal state of subdivision to enhance oral bioavailab - ,71 . 9 ility. It also relates to processes for the preparation of such compositions and using those compositions for the treatment of Chronic Myeloid Leukemia and other tumors such as head and neck cancer, prostate cancer and the like.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN6951CH2015 | 2015-12-18 | ||
| PCT/IN2016/050035 WO2017103941A1 (en) | 2015-12-18 | 2016-01-30 | Pharmaceutical compositions comprising phenylaminopyrimidine derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805142RA true SG11201805142RA (en) | 2018-07-30 |
Family
ID=59055898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805142RA SG11201805142RA (en) | 2015-12-18 | 2016-01-30 | Pharmaceutical compositions comprising phenylaminopyrimidine derivative |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US10383872B2 (en) |
| EP (1) | EP3389633B1 (en) |
| JP (2) | JP6896738B2 (en) |
| KR (1) | KR20180102584A (en) |
| CN (1) | CN108495620B (en) |
| AU (1) | AU2016373574B2 (en) |
| BR (1) | BR112018012458A2 (en) |
| CA (1) | CA3008634A1 (en) |
| CL (1) | CL2018001590A1 (en) |
| CO (1) | CO2018007112A2 (en) |
| CY (1) | CY1124580T1 (en) |
| DK (1) | DK3389633T3 (en) |
| EA (1) | EA036513B1 (en) |
| ES (1) | ES2881883T3 (en) |
| GB (1) | GB2564262A (en) |
| GE (1) | GEP20207176B (en) |
| HK (1) | HK1254573A1 (en) |
| HR (1) | HRP20211590T1 (en) |
| HU (1) | HUE056269T2 (en) |
| IL (1) | IL260085B (en) |
| LT (1) | LT3389633T (en) |
| MA (1) | MA44079B1 (en) |
| MX (1) | MX2018007281A (en) |
| PH (1) | PH12018501292A1 (en) |
| PL (1) | PL3389633T3 (en) |
| PT (1) | PT3389633T (en) |
| RS (1) | RS62422B1 (en) |
| SG (1) | SG11201805142RA (en) |
| SI (1) | SI3389633T1 (en) |
| UA (1) | UA122592C2 (en) |
| WO (1) | WO2017103941A1 (en) |
| ZA (1) | ZA201804203B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202246215A (en) | 2015-12-18 | 2022-12-01 | 美商亞德利克斯公司 | Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists |
| CZ2017821A3 (en) * | 2017-12-20 | 2019-07-03 | Zentiva, K.S. | Dosing of crystalline nilotinib |
| JP7333340B2 (en) * | 2018-05-14 | 2023-08-24 | キャプシュゲル・ベルジウム・エヌ・ヴィ | Solid dosage form with high active drug loading |
| JP7368548B2 (en) * | 2021-07-02 | 2023-10-24 | 昊運股▲フン▼有限公司 | Pharmaceutical compositions and uses thereof |
| CN115583634B (en) * | 2022-09-21 | 2023-06-06 | 广东工业大学 | Preparation method and application of carbon-nitrogen polymer material |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002241268A (en) * | 2000-12-11 | 2002-08-28 | Takeda Chem Ind Ltd | Pharmaceutical composition having improved water dispersibility |
| AP2470A (en) | 2004-09-09 | 2012-09-17 | Natco Pharma Ltd | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase |
| US8067422B2 (en) | 2008-03-04 | 2011-11-29 | Natco Pharma Limited | Crystal form of phenylamino pyrimidine derivatives |
| WO2012002547A1 (en) * | 2010-07-02 | 2012-01-05 | 富士化学工業株式会社 | Bosentan solid dispersion |
| GB2488788B (en) * | 2011-03-07 | 2013-07-10 | Natco Pharma Ltd | Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response |
| CN102836159B (en) * | 2011-06-24 | 2014-12-10 | 南京圣和药业股份有限公司 | Dasatinib dispersoid, preparation method thereof and application thereof in tablets |
| EP3082803A4 (en) * | 2013-12-20 | 2017-05-31 | Phosphorex Inc. | Indirubin solid dispersion composition |
-
2016
- 2016-01-30 US US16/062,320 patent/US10383872B2/en not_active Expired - Fee Related
- 2016-01-30 AU AU2016373574A patent/AU2016373574B2/en not_active Expired - Fee Related
- 2016-01-30 SI SI201631339T patent/SI3389633T1/en unknown
- 2016-01-30 GE GEAP201614833A patent/GEP20207176B/en unknown
- 2016-01-30 GB GB1811142.7A patent/GB2564262A/en not_active Withdrawn
- 2016-01-30 SG SG11201805142RA patent/SG11201805142RA/en unknown
- 2016-01-30 CN CN201680079960.9A patent/CN108495620B/en not_active Expired - Fee Related
- 2016-01-30 HU HUE16875074A patent/HUE056269T2/en unknown
- 2016-01-30 ES ES16875074T patent/ES2881883T3/en active Active
- 2016-01-30 UA UAA201806892A patent/UA122592C2/en unknown
- 2016-01-30 KR KR1020187020546A patent/KR20180102584A/en not_active Application Discontinuation
- 2016-01-30 RS RS20211232A patent/RS62422B1/en unknown
- 2016-01-30 MX MX2018007281A patent/MX2018007281A/en active IP Right Grant
- 2016-01-30 BR BR112018012458A patent/BR112018012458A2/en not_active IP Right Cessation
- 2016-01-30 EP EP16875074.3A patent/EP3389633B1/en active Active
- 2016-01-30 JP JP2018532262A patent/JP6896738B2/en active Active
- 2016-01-30 PT PT168750743T patent/PT3389633T/en unknown
- 2016-01-30 DK DK16875074.3T patent/DK3389633T3/en active
- 2016-01-30 MA MA44079A patent/MA44079B1/en unknown
- 2016-01-30 PL PL16875074T patent/PL3389633T3/en unknown
- 2016-01-30 WO PCT/IN2016/050035 patent/WO2017103941A1/en active Application Filing
- 2016-01-30 CA CA3008634A patent/CA3008634A1/en not_active Abandoned
- 2016-01-30 HR HRP20211590TT patent/HRP20211590T1/en unknown
- 2016-01-30 EA EA201891443A patent/EA036513B1/en unknown
- 2016-01-30 LT LTEPPCT/IN2016/050035T patent/LT3389633T/en unknown
-
2018
- 2018-06-14 CL CL2018001590A patent/CL2018001590A1/en unknown
- 2018-06-17 IL IL260085A patent/IL260085B/en unknown
- 2018-06-18 PH PH12018501292A patent/PH12018501292A1/en unknown
- 2018-06-22 ZA ZA2018/04203A patent/ZA201804203B/en unknown
- 2018-07-09 CO CONC2018/0007112A patent/CO2018007112A2/en unknown
- 2018-10-30 HK HK18113869.1A patent/HK1254573A1/en unknown
-
2020
- 2020-12-03 JP JP2020201322A patent/JP2021059551A/en not_active Withdrawn
-
2021
- 2021-10-13 CY CY20211100881T patent/CY1124580T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900077QA (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
| SG11201810034XA (en) | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201805142RA (en) | Pharmaceutical compositions comprising phenylaminopyrimidine derivative | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201407397WA (en) | Formulations and methods for vaginal delivery of antiprogestins | |
| SG11201407340YA (en) | Treatment of myelosuppression | |
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201407988UA (en) | Process for improved opioid synthesis | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201804048WA (en) | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor | |
| SG11201407599SA (en) | Oligonucleotide chelate complex-polypeptide compositions and methods | |
| SG11201408230VA (en) | Therapeutic formulation and methods of treatment |